Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA7 | P43166 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31737574 | 1.00 | IDO1 (0.52) | IDO1TAAR1CHRM2CHRM1ALDH1A1 | |
| SCHEMBL15311922 | 0.83 | IDO1 (0.55) | IDO1TAAR1CHRM2CHRM1ALDH1A1 | |
| SCHEMBL1093645 | 0.81 | IDO1 (0.53) | IDO1TAAR1CHRM2CHRM1ALDH1A1 | |
| SCHEMBL31737743 | 0.81 | IDO1 (0.53) | IDO1TAAR1CHRM2CHRM1ALDH1A1 | |
| SCHEMBL2908417 | 0.80 | L3MBTL1 (0.55) | ALDH1A1GAAMAPTGRIN1L3MBTL1 | |
| SCHEMBL5249922 | 0.79 | IDO1 (0.52) | IDO1TAAR1CHRM2CHRM1ALDH1A1 | |
| SCHEMBL5248188 | 0.79 | SLC6A2 (0.40) | ALDH1A1MAPTACHELMNASMN1; SMN2 | |
| SCHEMBL2904501 | 0.79 | SLC6A2 (0.43) | ALDH1A1KDM4E | |
| SCHEMBL6935700 | 0.76 | HRH1 (0.55) | ALDH1A1GAALMNAL3MBTL1 | |
| SCHEMBL5245595 | 0.76 | CACNA1G (0.39) | ALDH1A1GAAMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | claimed |
| JP-57074306-A | — | — | None | — | — | JP | disclosed |
| WO-2025242747-A1 | MULTI -COMPONENT FORMULATIONS OF ORGANOMETALLIC REAGENTS | MERCK PATENT GMBH (DE) | 2025-11-27 | — | — | WO | disclosed |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | GILEAD SCIENCES, INC. (US) | 2024-07-30 | — | — | US | disclosed |
| US-11701373-B2 | Substituted bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-07-18 | — | — | US | disclosed |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| EP-4144735-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20220331346-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-20 | — | — | US | disclosed |
| US-20220313676-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA, INC. | 2022-10-06 | — | — | US | disclosed |
| EP-3523302-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2022-07-20 | — | — | EP | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6861566-B2 | Process for producing 1-chloro-4-arylbutane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-03-01 | — | — | US | disclosed |
| US-20050043301-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-24 | — | — | US | disclosed |
| US-20040097763-A1 | Process for producing 1-chloro-4-arylbutane | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-05-20 | — | — | US | disclosed |
| WO-2004033466-A1 | OXYGEN-CONTAINING ORGANOALUMINUM COMPLEXES USED AS COCATALYSTS | MERCK PATENT GMBH (DE) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004009603-A1 | DIHYDRO-DIBENZO[B,E]OXEPINE BASED SELECTIVE ESTROGEN RECEPTOR MODULATORS, COMPOSITIONS AND METHODS | ELI LILLY AND COMPANY (US) | 2004-01-29 | — | — | WO | disclosed |
| EP-1369405-A1 | PROCESS FOR PRODUCING 1-CHLORO-4-ARYLBUTANE | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2003-12-10 | — | — | EP | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-4411913-A | OTHER SPIRO COMPOUNDS, CARDIOVASCULAR DISORDERS, HYPOTENSIVE, ANTIEDEMIC, ANTILIPEMIC, HYPOGLYCEMIC, ANOREXIGENIC | SANDOZ LTD. (CH) | 1983-10-25 | — | — | US | disclosed |
| JP-S5774306-A | PRODUCTION OF POLYOLEFIN | NIPPON OIL CO LTD | 1982-05-10 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043301-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | IDO1 520/4885TAAR1 3133/4885CHRM2 117/4885 |
| US-12049461-B2 | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections | NR3C1, NR3C2, NR4A1 | IDO1 1289/4885TAAR1 319/4885CHRM2 581/4885 |
| US-20220331346-A1 | SUBSTITUTED BICYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR2 | IDO1 786/4885TAAR1 179/4885CHRM2 162/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | IDO1 4158/4885TAAR1 1974/4885CHRM2 2821/4885 |
| US-11701373-B2 | Substituted bicyclic compounds | S1PR1, S1PR3, S1PR2 | IDO1 786/4885TAAR1 179/4885CHRM2 162/4885 |
| US-20220313676-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | IDO1 4158/4885TAAR1 1974/4885CHRM2 2821/4885 |
| US-20040097763-A1 | Process for producing 1-chloro-4-arylbutane | CYP1B1, CBR1, CYP1A1 | IDO1 114/4885TAAR1 77/4885CHRM2 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.